Expert opinion in biological therapy: update on developments in lung gene transfer

被引:18
作者
Griesenbach, Uta [3 ]
Alton, Eric W. F. W. [1 ,2 ]
机构
[1] Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, Dept Gene Therapy, London SW3 6LR, England
[2] UK Cyst Fibrosis Gene Therapy Consortium, London, England
[3] Univ London Imperial Coll Sci Technol & Med, Dept Gene Therapy, London SW3 6LR, England
关键词
acute lung injury; airways; alpha 1-antitrypsin deficiency; asthma; chronic obstructive pulmonary disease; cystic fibrosis; gene therapy; lung infection; lung transplantation; non-viral gene transfer agents; primary ciliary dyskinesia; surfactant protein B deficiency; viral gene transfer agents; TRANSMEMBRANE CONDUCTANCE REGULATOR; RECOMBINANT ADENOASSOCIATED VIRUS; SUSTAINED TRANSGENE EXPRESSION; KERATINOCYTE GROWTH-FACTOR; CPG-FREE PLASMIDS; CYSTIC-FIBROSIS; AIRWAY EPITHELIUM; IN-VIVO; SENDAI-VIRUS; DIRECTED EVOLUTION;
D O I
10.1517/14712598.2013.735656
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Introduction: Gene therapy may be suitable for a large number of acquired and inherited lung diseases, and research efforts in the field are vast. Although gene transfer to the lung has proven more challenging than initially anticipated, significant progress has been made over the last 10 years. Areas covered: Here, we will first review viral and non-viral gene transfer agents that have been assessed for lung gene therapy and discuss key barriers to pulmonary gene transfer. We will then review progress in gene therapy for various lung diseases. Expert opinion: In our view, one of the most significant developments in recent years is the generation of lentiviral vectors which efficiently transduce lung tissue. Focused and coordinated efforts assessing lentivirus safety and scaling up lentivirus production will be required to move this vector into clinical lung gene therapy studies. Although market authorization for a lung gene therapy product is not yet available, we are optimistic that this key milestone can be achieved in the next few years.
引用
收藏
页码:345 / 360
页数:16
相关论文
共 122 条
[1]   Bone Marrow Stem Cells Expressing Keratinocyte Growth Factor via an Inducible Lentivirus Protects against Bleomycin-Induced Pulmonary Fibrosis [J].
Aguilar, Susana ;
Scotton, Chris J. ;
McNulty, Katrina ;
Nye, Emma ;
Stamp, Gordon ;
Laurent, Geoff ;
Bonnet, Dominique ;
Janes, Sam M. .
PLOS ONE, 2009, 4 (11)
[2]   Gene therapy for chronic obstructive pulmonary disease: twilight or triumph? [J].
Al-Jamal, R ;
Wallace, WAH ;
Harrison, DJ .
EXPERT OPINION ON BIOLOGICAL THERAPY, 2005, 5 (03) :333-346
[3]   Cationic lipid-mediated CFTR gene transfer to the lungs and nose of patients with cystic fibrosis:: a double-blind placebo-controlled trial [J].
Alton, EWFW ;
Stern, M ;
Farley, R ;
Jaffe, A ;
Chadwick, SL ;
Phillips, J ;
Davies, J ;
Smith, SN ;
Browning, J ;
Davies, MG ;
Hodson, ME ;
Durham, SR ;
Li, D ;
Jeffery, PK ;
Scallan, M ;
Balfour, R ;
Eastman, SJ ;
Cheng, SH ;
Smith, AE ;
Meeker, D ;
Geddes, DM .
LANCET, 1999, 353 (9157) :947-954
[4]   NONINVASIVE LIPOSOME-MEDIATED GENE DELIVERY CAN CORRECT THE ION-TRANSPORT DEFECT IN CYSTIC-FIBROSIS MUTANT MICE [J].
ALTON, EWFW ;
MIDDLETON, PG ;
CAPLEN, NJ ;
SMITH, SN ;
STEEL, DM ;
MUNKONGE, FM ;
JEFFERY, PK ;
GEDDES, DM ;
HART, SL ;
WILLIAMSON, R ;
FASOLD, KI ;
MILLER, AD ;
DICKINSON, P ;
STEVENSON, BJ ;
MCLACHLAN, G ;
DORIN, JR ;
PORTEOUS, DJ .
NATURE GENETICS, 1993, 5 (02) :135-142
[5]   RNA Interference-Mediated Silencing of the Respiratory Syncytial Virus Nucleocapsid Defines a Potent Antiviral Strategy [J].
Alvarez, Rene ;
Elbashir, Sayda ;
Borland, Todd ;
Toudjarska, Ivanka ;
Hadwiger, Philipp ;
John, Mathias ;
Roehl, Ingo ;
Morskaya, Svetlana Shulga ;
Martinello, Rick ;
Kahn, Jeffrey ;
Van Ranst, Mark ;
Tripp, Ralph A. ;
DeVincenzo, John P. ;
Pandey, Rajendra ;
Maier, Martin ;
Nechev, Lubomir ;
Manoharan, Muthiah ;
Kotelianski, Victor ;
Meyers, Rachel .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2009, 53 (09) :3952-3962
[6]   Frontrunners in novel pharmacotherapy of COPD [J].
Barnes, Peter J. .
CURRENT OPINION IN PHARMACOLOGY, 2008, 8 (03) :300-307
[7]   The significance of plasmid DNA preparations contaminated with bacterial genomic DNA on inflammatory responses following delivery of lipoplexes to the murine lung [J].
Bazzani, Reto P. ;
Cai, Ying ;
Hebel, Henry L. ;
Hyde, Stephen C. ;
Gill, Deborah R. .
BIOMATERIALS, 2011, 32 (36) :9854-9865
[8]   The AAV9 receptor and its modification to improve in vivo lung gene transfer in mice [J].
Bell, Christie L. ;
Vandenberghe, Luk H. ;
Bell, Peter ;
Limberis, Maria P. ;
Gao, Guang-Ping ;
Van Vliet, Kim ;
Agbandje-McKenna, Mavis ;
Wilson, James M. .
JOURNAL OF CLINICAL INVESTIGATION, 2011, 121 (06) :2427-2435
[9]   Gene therapy for primary immunodeficiency [J].
Booth, Claire ;
Gaspar, H. Bobby ;
Thrasher, Adrian J. .
CURRENT OPINION IN PEDIATRICS, 2011, 23 (06) :659-666
[10]   Phase I trial of intramuscular injection of a recombinant adeno-associated virus serotype 2 α1-antitrypsin (AAT) vector in AAT-deficient adults [J].
Brantly, Mark L. ;
Spencer, L. Terry ;
Humphries, Margaret ;
Conlon, Thomas J. ;
Spencer, Carolyn T. ;
Poirier, Amy ;
Garlington, Wendy ;
Baker, Dawn ;
Song, Sihong ;
Berns, Kenneth I. ;
Muzyczka, Nicholas ;
Snyder, Richard O. ;
Byrne, Barry J. ;
Flotte, Terence R. .
HUMAN GENE THERAPY, 2006, 17 (12) :1177-1186